The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-05 and is reviewed periodically as new material appears.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
ADAM17 is an 824-amino acid polypeptide. ADAM17 has multidomain structure that includes a pro-domain, a metallo-protease domain, a disintegrin domain, a cysteine-rich domain, an EGF-like domain, a transmembrane domain, and a cytoplasmic tail. The metalloprotease domain is responsible for the enzyme's catalytic activity, cleaving membrane-bound proteins, including cytokines like TNF-alpha, to release their soluble forms. The disintegrin and cysteine-rich domains are implicated in cell adhesion and interaction with integrins, while the transmembrane domain anchors the protein in the membrane. The cytoplasmic tail is involved in intracellular signaling and protein-protein interactions. ADAM17's activity is tightly regulated through multiple mechanisms, including the removal of its pro-domain and interactions with regulatory proteins such as TIMPs (tissue inhibitors of metalloproteinases).
=== Pregnancy === Methocarbamol is labeled by the FDA as a pregnancy category C medication. The teratogenic effects of the medication are not known and it should be given to pregnant women only when indicated.
Insulin degludec/liraglutide, sold under the brand name Xultophy, is a fixed-dose combination medication for the treatment of adults with type 2 diabetes to improve glycemic control in combination with diet and exercise. It contains insulin degludec and liraglutide. It is administered by subcutaneous injection. The most common side effects include hypoglycaemia (low blood glucose). Side effects on the digestive system include nausea (feeling sick), diarrhea, vomiting, constipation, dyspepsia (indigestion), gastritis (inflammation of the stomach), abdominal pain (stomach ache), flatulence (wind), gastroesophageal reflux disease (passage of stomach acid back up towards the mouth), and distension (swelling) of the belly. Insulin degludec is a replacement insulin that acts in the same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced. Insulin degludec is slightly different from human insulin as it is absorbed more slowly and regularly by the body after an injection and it works for a long time. Liraglutide belongs to the class of diabetes medicines known as GLP-1 receptor agonists It acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.
Sources: en.wikipedia.org
In 1937, Conrad Elvehjem, a biochemistry professor at the University of Wisconsin-Madison, showed that the vitamin B3 cured pellagra (manifested as black tongue) in dogs. Later studies by Dr. Tom Spies, Marion Blankenhorn, and Clark Cooper established that niacin also cured pellagra in humans, for which Time dubbed them its 1938 Men of the Year in comprehensive science. Research conducted between 1900 and 1950 found the number of cases of women with pellagra was consistently double the number of cases of affected men. This is thought to be due to the inhibitory effect of estrogen on the conversion of the amino acid tryptophan to nicotinic acid mononucleotide (NaMN). Some researchers of the time gave a few explanations regarding the difference. Gillman and Gillman related skeletal tissue and pellagra in their research in South Africans. They provide some of the best evidence for skeletal manifestations of pellagra and the reaction of bone in malnutrition. They claimed radiological studies of adult pellagrins demonstrated marked osteoporosis. A negative mineral balance in pellagrins was noted, which indicated active mobilization and excretion of endogenous mineral substances, and undoubtedly impacted the turnover of bone. Extensive dental caries were present in over half of pellagra patients. In most cases, caries were associated with "severe gingival retraction, sepsis, exposure of cementum, and loosening of teeth".
The nuclear plants have further been questioned as a source of the cases due to comparison to the Savannah River Site in the United States. Despite the release of radiation at the Savannah River Site, there is no increase in cases of leukemia around it. Alternative hypotheses for the cause of the cases have included electromagnetic fields, parental radiation exposure before conception, other carcinogens, and benzene exposure; however, none have been supported by the existing evidence. Intriguingly, a larger case-control study in Lower Saxony found a correlation between the "untrained immune system" (as judged as contact with other children, vaccinations, etc.) and leukemia risk, suggested that an immature immune system that has not been challenged is at greater risk for developing malignancy, possibly secondary to an undetermined environment factor.
=== Bibliography === Hamburg Institute for Social Research, ed. (1999). The German Army and Genocide: Crimes Against War Prisoners, Jews, and Other Civilians in the East, 1939-1944. New York: New Press. ISBN 978-1-56584-525-1. Jentz, Thomas (1996). Panzertruppen Vol. 2 The Complete Guide to the Creation & Combat Employment of Germany's Tank Force 1943-1945. Atglen, PA: Schiffer Publishing. ISBN 0-7643-0080-6. Nafziger, George. "Organizational History of Miscelleanous German Named Infantry and Panzer Grenadier, Brigades, Verbands & Divisions, 1939-1945" (PDF). Combined Arms Research Library Digital Library. US Army Combined Arms Center. Retrieved 10 July 2016. Scheibert, Horst (1987). Culver, Bruce (ed.). Panzer Grenadier Division Grossdeutschland: A Pictorial History with Text & Maps. Translated by Gisele Hockenberry. Carrollton, Texas: Squadron/Signal Publications. ISBN 0-89747-061-3. Sharpe, Michael & Davis, Brian L (2001). Grossdeutschland: Guderian's Eastern Front Elite. Compendium Publishing. ISBN 0-7110-2854-0. Solarz, Jacek (2005). Division/Korps Großdeutschland 1943-1945. Vol. I and II. Warsaw: Wydawnictwo Militaria. ISBN 83-7219-237-5. Spaeter, Helmuth (1992). The History of the Panzerkorps Großdeutschland Vol I. Winnipeg, Canada: J. J. Fedorowicz Publishing. ISBN 0-921991-12-6. Spaeter, Helmuth (1995). The History of the Panzerkorps Großdeutschland Vol II. Winnipeg, Canada: J. J. Fedorowicz Publishing. ISBN 0-921991-27-4. Spaeter, Helmuth (2000). The History of the Panzerkorps Großdeutschland Vol III. Winnipeg, Canada: J. J. Fedorowicz Publishing.
=== Dosing === Although doxycycline is approved to treat Lyme disease, the optimal dosing and duration of treatment for this condition is a topic of ongoing research. it can be used in adults and children. For treatment or prophylaxis of Lyme disease in children, it can be used for a duration of up to 21 days in children of any age. Doxycycline is specifically indicated to treat Lyme disease for patients presenting with erythema migrans. As for the optimal duration of treatment of this disease, guidelines vary, with some recommending a 10-day course of doxycycline, while others suggest a 14-day course; still, recent data suggest that even a 7-day course of doxycycline can be effective. Compared to other drugs, there are no significant differences in treatment response across antibiotic agents, doses, or durations when comparing 14 days versus 21 days; as such, the optimal duration of treatment of Lyme disease remains uncertain, as prolonged antibiotic courses have drawbacks, including diminishing returns in terms of patient outcomes, heightened risks of adverse events, superinfections, increased healthcare costs, and the potential for development of antibiotic resistance. Therefore, the consensus remains to treat patients with the shortest effective duration of antibiotics, as is the case with doxycycline for Lyme disease as well.
Sources: en.wikipedia.org
=== Policy reforms and sustainable management === Singh reoriented forest plans toward industrial applications while ensuring regeneration. His notable policy contributions included: The Hari Singh Committee (1967): As chair of the Committee on Tribal Economy in Forest Areas, he recommended eliminating exploitative intermediaries in the timber trade. The committee proposed establishing Forest Labourers’ Co-operative Societies to engage local indigenous communities in afforestation, harvesting, and minor forest produce collection. Social forestry: He introduced the concept of "social forestry" to India to preserve local greenery, provide firewood, and prevent soil erosion. Industrial and development schemes: He formulated the "Quick Growing Species" scheme to sustain yields for industries like paper mills and railways. He also initiated two major UNDP projects in India: the Pre-investment Survey of Forest Resources and the Logging Training Centre Project. Legislative advocacy: Singh was instrumental in efforts that eventually led to the 42nd Amendment of the Constitution, which transferred forestry to the concurrent list, allowing for greater federal oversight.
Acute and chronic exposure also reduces glutathione reductase, an enzyme that catalyzes the reduction of glutathione disulfide (GSSG) to the sulfhydryl form glutathione (GSH), which is a critical molecule in resisting oxidative stress and maintaining the reducing environment of the cell.
incorporates its gross from the 1985 reissue but not from 2002. The total for Avatar's first appearance on the chart includes revenue from the 2010 Special Edition, which represents all of its earnings up to the point it relinquished the record, whereas its second appearance also incorporates revenue from a 2020 re-release in the Asia-Pacific region as well as the 2021 re-release in China which helped it to reclaim the record. Gone with the Wind is likewise represented twice on the chart: the 1940 entry includes earnings from its staggered 1939–1942 release (roadshow/general release/second-run) along with all of its revenue up to the 1961 reissue prior to losing the record to The Sound of Music in 1966; its 1971 entry—after it took back the record—includes income from the 1967 and 1971 reissues but omitting later releases. The Godfather was re-released in 1973 after its success at the 45th Academy Awards, and Jaws was released again in 1976, and their grosses here most likely include earnings from those releases. The Sound of Music, The Godfather, Jaws, Jurassic Park, and Titanic have all increased their earnings with further releases, but they are not included in the totals here because they had already conceded the record prior to being re-released.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.